Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotic Development: HHS Not Yet Sold On ‘Pull’ Incentives

Executive Summary

As HHS develops strategic framework to combat antibiotic resistance, post-market financial incentives may not be included, despite prominent government panels recommending the idea years ago and GAO urging the department to do so in a just-released report. Stakeholders told that GAO reimbursement reform won't be enough to spur a strong antibiotic pipeline.

You may also be interested in...



‘FDA Is Not the Villain:’ Study Highlights Need For Post-Market Focus To Spur Antibiotics

A study of drug approvals over more than three decades shows antimicrobials, including antibacterials, had consistently shorter development and review times than other types of products. While antibacterials were less likely to participate in special US FDA programs designed to help along review, experts said reimbursement reform, not new regulatory flexibility, is needed to help address the crisis of drug-resistant infections. 

Antibiotics Could See New Boosts From Medicare Rule, House Bill

US House looks to give BARDA more money for antibiotic development in next coronavirus relief bill, while Medicare broadens the types of antibiotics eligible for additional payments to include drugs approved under FDA's limited population antibiotic development pathway. But it's unclear whether the House funding can make it through the Senate and how meaningful the Medicare provision will be given few LPAD approvals.

Antibiotic Incentives: Prize Fund Is Focus Of Presidential Report On Incentives

Upcoming White House report on antibiotic incentives will provide a strong endorsement of one-time payments to reward successful development of new therapeutics. That is a mixed blessing for advocates for legislative action for incentives who are focusing on 'wildcard' patents.

Related Content

Topics

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel